CNTB Stock Summary and Trading Ideas (Connect Biopharma Hldgs | NASDAQ:CNTB)

Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

Connect Biopharma Hldgs trades on the NASDAQ stock market under the symbol CNTB.

As of May 29, 2026, CNTB stock price climbed to $2.49 with 266,664 million shares trading.

CNTB has a beta of -2.48, meaning it tends to be less sensitive to market movements. CNTB has a correlation of 0.10 to the broad based SPY ETF.

CNTB has a market cap of $156.78 million. This is considered a Micro Cap stock.

In the last 3 years, CNTB traded as high as $3.82 and as low as $.51.

CNTB has outperformed the market in the last year with a price return of +219.2% while the SPY ETF gained +29.5%. However, in the short term, CNTB had mixed performance relative to the market. It has underperformed in the last 3 months, returning +0.8% vs +10.5% return in SPY. But in the last 2 weeks, CNTB shares have fared better than the market returning +4.6% compared to SPY +2.3%.

CNTB support price is $2.24 and resistance is $2.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CNTB shares will trade within this expected range on the day.